Wei Wang
Direktor/Vorstandsmitglied bei MingMed Biotechnology Co., Ltd.
Profil
Wei Wang is currently a Member-Supervisory Board at MingMed Biotechnology Co., Ltd.
He obtained an MBA from The University of Hull in 2003.
Aktive Positionen von Wei Wang
| Unternehmen | Position | Beginn |
|---|---|---|
MingMed Biotechnology Co., Ltd.
 MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | Direktor/Vorstandsmitglied | 24.06.2022 |
Ausbildung von Wei Wang
| The University of Hull | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | Health Technology |